Skip to content

Ovarian Cancer Health Center

Medical Reference Related to Ovarian Cancer

  1. Ovarian Germ Cell Tumors Treatment (PDQ®): Treatment - Patient Information [NCI] - Changes to This Summary (03 / 20 / 2013)

    The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.Editorial changes were made to this summary.

  2. Ovarian Germ Cell Tumors Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Recurrent Ovarian Germ Cell Tumors

    DysgerminomasStandard treatment options:Cisplatin-based chemotherapy has been used effectively for patients with recurrent dysgerminoma with and without adjuvant radiation therapy.[1]Treatment options under clinical evaluation:Patients with recurrent pure dysgerminoma of the ovary are candidates for clinical trials, such as (GOG-90), which has been closed. Some consideration should be given to the use of high-dose regimens with rescue. Other Germ Cell TumorsStandard treatment options:Patients with recurrent germ cell tumors of the ovary other than pure dysgerminoma should be treated with chemotherapy, the type of which is determined by previous treatment.[2] Radiation therapy is not effective in this setting. Cisplatin-based combination chemotherapy is effective.[1,3,4] Patients who do not respond to a cisplatin-based combination may still attain a durable remission with VAC or ifosfamide/cisplatin as salvage therapy.[1] Newer potential treatments include an ifosfamide combination [5]

  3. Ovarian Cancer Prevention (PDQ®): Prevention - Patient Information [NCI] - What is prevention?

    WebMD discusses methods of preventing ovarian cancer.

  4. Ovarian Low Malignant Potential Tumors Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage Information for Ovarian Low Malignant Potential Tumors

    Definitions: FIGOThe Féderation Internationale de Gynécologie et d'Obstétrique (FIGO) and the American Joint Committee on Cancer (AJCC) have designated staging to define ovarian low malignant potential tumors; the FIGO system is most commonly used.[1,2]Table 1. Carcinoma of the OvaryaStagea Adapted from FIGO Committee on Gynecologic Oncology.[1]b In order to evaluate the impact on prognosis of the different criteria for allotting cases to stage Ic or IIc, it would be of value to know if rupture of the capsule was spontaneous, or caused by the surgeon; and if the source of malignant cells detected was peritoneal washings, or ascites.IGrowth limited to the ovaries.IaGrowth limited to one ovary; no ascites present containing malignant cells. No tumor on the external surface; capsule intact.IbGrowth limited to both ovaries; no ascites present containing malignant cells. No tumor on the external surfaces; capsules intact.IcbTumor either stage Ia or Ib, but with tumor on surface of one

  5. Ovarian Germ Cell Tumors Treatment (PDQ®): Treatment - Patient Information [NCI] - Treatment Options for Recurrent Ovarian Germ Cell Tumors

    Treatment depends on whether the tumor is a dysgerminoma or another type of ovarian germ cell tumor. Treatment of dysgerminoma may be:Chemotherapy with or without radiation therapy.Treatment of other ovarian germ cell tumors may include the following: Chemotherapy.Surgery with or without chemotherapy.A clinical trial of high-dose chemotherapy followed by bone marrow transplant.A clinical trial of a new treatment.Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with recurrent ovarian germ cell tumor. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. General information about clinical trials is available from the NCI Web site.

  6. Ovarian Epithelial Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage Information for Ovarian Epithelial Cancer

    In the absence of extra-abdominal metastatic disease, definitive staging of ovarian cancer requires surgery. The role of surgery in patients with stage IV disease and extra-abdominal disease is yet to be established. If disease appears to be limited to the ovaries or pelvis, it is essential at laparotomy to examine and biopsy or to obtain cytologic brushings of the diaphragm, both paracolic gutters, the pelvic peritoneum, para-aortic and pelvic nodes, and infracolic omentum, and to obtain peritoneal washings.[1]The serum CA 125 level is valuable in the follow-up and restaging of patients who have elevated CA 125 levels at the time of diagnosis.[2,3,4] While an elevated CA 125 level indicates a high probability of epithelial ovarian cancer, a negative CA 125 level cannot be used to exclude the presence of residual disease.[5] CA 125 levels can also be elevated in other malignancies and benign gynecologic problems such as endometriosis, and CA 125 levels should be used with a

  7. Ovarian Epithelial Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - To Learn More About Ovarian Epithelial Cancer

    For more information from the National Cancer Institute about ovarian epithelial cancer, see the following:Ovarian Cancer Home PageWhat You Need to Know About™ Ovarian CancerOvarian Cancer PreventionOvarian Cancer ScreeningUnusual Cancers of ChildhoodDrugs Approved for Ovarian CancerUnderstanding Cancer Series: Targeted Therapies (Advances in Targeted Therapies)Targeted Cancer TherapiesBRCA1 and BRCA2: Cancer Risk and Genetic TestingGenetic Testing for Hereditary Cancer SyndromesFor general cancer information and other resources from the National Cancer Institute, see the following:What You Need to Know About™ CancerUnderstanding Cancer Series: CancerCancer StagingChemotherapy and You: Support for People With CancerRadiation Therapy and You: Support for People With CancerCoping with Cancer: Supportive and Palliative CareQuestions to Ask Your Doctor About CancerCancer LibraryInformation For Survivors/Caregivers/Advocates

  8. Ovarian Low Malignant Potential Tumors Treatment (PDQ®): Treatment - Patient Information [NCI] - About This PDQ Summary

    About PDQPhysician Data Query (PDQ) is the National Cancer Institute's (NCI's) comprehensive cancer information database. The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries come in two versions. The health professional versions have detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions have cancer information that is accurate and up to date and most versions are also available in Spanish.PDQ is a service of the NCI. The NCI is part of the National Institutes of Health (NIH). NIH is the federal government's center of biomedical research. The PDQ summaries are based on an independent review of the medical literature. They are not policy statements of the NCI or the NIH.Purpose of This SummaryThis PDQ cancer information summary has current

  9. Ovarian Cancer Prevention (PDQ®): Prevention - Health Professional Information [NCI] - Significance

    Incidence and Mortality In 2013, it is estimated that 22,240 new cases of ovarian cancer will be diagnosed and 14,030 deaths due to ovarian cancer will occur. Incidence rates have been relatively stable since 1992. Death rates for ovarian cancer decreased by 2.0% per year from 2005 to 2009.[1]For the general population of women, the lifetime risk of developing ovarian cancer is 1.39%; the lifetime risk of dying from ovarian cancer is 1.04%.[2] Some women are at an increased risk due to an inherited susceptibility to ovarian cancer with the magnitude of that risk depending on the affected gene and specific mutation. Underlying ovarian cancer risk can be assessed through accurate pedigrees and/or genetic markers of risk. Because of uncertainties about cancer risks associated with specific gene mutations, genetic information may be difficult to interpret outside of families with a high incidence of ovarian cancer. Three inherited ovarian cancer susceptibility syndromes have been

  10. Ovarian Cancer Prevention (PDQ®): Prevention - Patient Information [NCI] - About This PDQ Summary

    About PDQPhysician Data Query (PDQ) is the National Cancer Institute's (NCI's) comprehensive cancer information database. The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries come in two versions. The health professional versions have detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions have cancer information that is accurate and up to date and most versions are also available in Spanish.PDQ is a service of the NCI. The NCI is part of the National Institutes of Health (NIH). NIH is the federal government's center of biomedical research. The PDQ summaries are based on an independent review of the medical literature. They are not policy statements of the NCI or the NIH.Purpose of This SummaryThis PDQ cancer information summary has current

Displaying 81 - 90 of 192 Articles << Prev Page 5 6 7 8 9 10 11 12 13 14 Next >>

Today on WebMD

Ovarian cancer illustration
What are the symptoms?
doctory with x-ray
Get to know the Symptoms.
 
cancer cell
HPV is the top cause. Find out more.
Lung cancer xray
See it in pictures, plus read the facts.
 
Integrative Medicine Cancer Quiz
QUIZ
Lifestyle Tips for Depression Slideshow
SLIDESHOW
 
Screening Tests for Women
Slideshow
Graphic of ovaries within reproductive system
VIDEO
 
Ovarian Cancer Marker
VIDEO
Pets Improve Your Health
SLIDESHOW
 
Vitamin D
SLIDESHOW
Healthy meal with salmon
Article